a public good project by the
Synthesis
Company
of California

© 2026

Rajeev Menon | doi.page

0 works0 citations0 h-index

Rajeev Menon

AbbVie (United States)(US)Renewable Spirits (United States)(US)Asian Institute of Gastroenterology(IN)National University Hospital(SG)

Publications by Year

Research Areas

Hepatitis C virus research, HIV/AIDS drug development and treatment, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments

Most-Cited Works

→ Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C(2013)285 cited
→ Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments(2017)226 cited
→ Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir(2015)125 cited
→ In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450(2014)117 cited
→ Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir(2015)83 cited
→ A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1

(2013)

69 cited

→ 1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS(2012)65 cited

→ Effect of the Rate of Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its Metabolites(2007)56 cited

→ Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy(2022)46 cited

→ Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation(2007)45 cited